Development of this comprehensive bispecific antibody program included policy development; toxicity management; creation of patient and staff education documents; creation of clinician tools like a toxicity scoring and charting tool and an electronic order set that segregates treatment options; and a monitoring system to safely transition patients from inpatient to outpatient care.
Munson Healthcare’s Cowell Family Cancer Center won a 2024 ACCC Innovator Award for its bispecific T-cell engager therapy program, which offers a viable alternative to CAR T-cell therapy for patients with relapsed and refractory cancers. Learn how this pharmacist-led program manages unique toxicities with meticulous planning and patient education in this month’s Oncology Issues.
